Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

–  Eplontersen showed statistically significant and clinically meaningful improvements in mNIS+7 and Norfolk QoL-DN –  Eplontersen demonstrated a favorable safety profile –  Ionis and AstraZeneca expect to file a New Drug Application this year CARLSBAD, Calif.